Bojana Stefanovska

1 month ago | nature.com | Avantika Gupta |Fresia Pareja |David Brown |Yingjie Zhu |Juan Blanco-Heredia |Bojana Stefanovska | +11 more

AbstractAcquired genetic alterations drive resistance to endocrine and targeted therapies in metastatic breast cancer; however, the underlying processes engendering these alterations are largely uncharacterized. To identify the underlying mutational processes, we utilized a clinically annotated cohort of 3,880 patient samples with tumor-normal sequencing.